Table 1.
Characteristics of the study population. Data are presented as mean (s.d.) or n (%).
| Variables | Acromegaly patients (n=48) | Control I (n=96) | Control II (n=475) |
|---|---|---|---|
| Sex | |||
| Female | 32 (67%) | 67 (70%) | 324 (68%) |
| Male | 16 (33%) | 29 (30%) | 151 (32%) |
| Age (years) | 55.8 (12.8) | 53.2 (17.4) | 54.3 (13.4) |
| BMI (kg/m2) | 29.9 (5.5) | 25.4 (4.4) | 27.6 (5.2) |
| Waist (cm) | 91.0 (13.7) | – | – |
| Age at diagnosis (years) | 47.4 (13.1) | – | – |
| Tumour size | |||
| Macroadenoma | 31 (64%) | – | – |
| Microadenoma | 17 (36%) | ||
| Effect of SA on tumor size (n=35) | |||
| Reduced | 11 (31.5%) | – | – |
| Unchanged | 24 (68.5%) | ||
| Expanded | |||
| Adenoma resections per patient | |||
| 1 | 23 (47.9%) | – | – |
| 2 | 2 (4.1%) | ||
| 3 | 2 (4.1%) | ||
| IGF1 norm | |||
| % ULN before treatment (n=20) | 178.8 (87.9) | – | – |
| % ULN after treatment (n=39) | 50.8 (77.8) | ||
| IGF1 responsiveness (n=39) | |||
| <ULN | 12 (30%) | ||
| >ULN | 27 (70%) |
BMI, body mass index; IGF1, insulin-like growth factor 1; ULN, upper limit of normal at corresponding age group; IGF1 norm, % ULN, normalized percentage of ULN ((CIGF1−ULNIGF1)/ULNIGF1×100)).